Every year, millions of meals result in abdominal pain, fever or much more serious complications. Behind these often trivialized symptoms lies a massive health issue, relegated to the background for too long. The cause is infectious agents as widespread as they are formidable, capable of striking without distinction of continent or social class. While health systems are struggling to stem cases of food poisoning, a team of researchers is now banking on an unexpected lever to reverse the trend.
In a phase I trial conducted on 22 healthy volunteers, all participants who received the vaccine developed a significant immune response, with high production of antibodies specific to the three targeted strains. No serious side effects have been reported, apart from temporary pain at the injection site. These results, published in Nature Medicine, validate the safety and immunogenicity of the vaccine candidate.
Why food poisoning remains a poorly controlled threat
Despite awareness campaigns and progress in food safety, poisoning linked to Salmonella bacteria persists at a high level. According to estimates from the Centers for Disease Control and Prevention, this bacteria alone causes 1.35 million cases in the United States each year, including more than 26,000 hospitalizations. It is even the leading cause of deaths linked to food poisoning in the country, with 238 deaths estimated in 2019.
The majority of infections occur after ingesting undercooked meat, poultry or eggs, but also contaminated fruits or vegetables. Contaminated water and human-to-human contact are also common vectors in some parts of the world.
In sub-Saharan Africa, the problem takes on a whole new dimension. University of Maryland Dean Mark Gladwin's report says that in 2017, there were more than 420,000 illnesses and 66,000 deaths in the region. In children, invasive forms are particularly dangerous, as they can spread outside the digestive system and cause serious complications.
Towards a preventive vaccine for all? Promises to be confirmed
The experimental vaccine, called TSCV, targets three major strains: the one responsible for typhoid fever and two others causing the most frequent invasive infections. This is a so-called conjugate vaccine, which combines polysaccharide antigens with carrier proteins to strengthen the immune response.
The phase I trial, which took place in the United States, made it possible to verify the tolerance of the vaccine and to observe simultaneous activation of humoral and cellular defenses. Encouraging results according to Professor Wilbur Chen, head of the study cited by Gizmodo, who underlines its potential for children living in areas where typhoid and Salmonella are continuously rampant.
In addition, some participants already had traces of immunity, probably acquired from past food infections. This observation could indicate a beneficial natural booster effect, to be confirmed by future trials.
It now remains to test the vaccine on a larger scale, particularly on young populations and in varied geographic contexts. The next phases will also have to evaluate the duration of protection and its effectiveness against bacterial mutations.
With an unwavering passion for local news, Christopher leads our editorial team with integrity and dedication. With over 20 years’ experience, he is the backbone of Wouldsayso, ensuring that we stay true to our mission to inform.
